INDEPENDENT THINKING. BETTER EVIDENCE.WEIGHT, HEALTH & THE SCIENCE BETWEEN
WEIGHT-LOSS DRUG TRACKER

Tirzepatide

Tirzepatide acts on GIP and GLP-1 receptors. Its approved uses depend on the product and jurisdiction, rather than following automatically from its dual-receptor mechanism.

A genuine Mounjaro KwikPen containing tirzepatide, with its original German-language label.
Genuine Mounjaro KwikPen in a German-language presentation. Original product photograph retained within an adjusted editorial frame. Branding and available products vary by country; the pictured dose is not dosing advice. © Raimond Spekking / CC BY-SA 4.0 (via Wikimedia Commons) Source: https://commons.wikimedia.org/wiki/File:Lilly_mounjaro_KwikPen_Tirzepatid_5_mg_per_dose_rate-9442.jpg License: https://creativecommons.org/licenses/by-sa/4.0. Layout and size adjusted.

Tirzepatide acts on GIP and GLP-1 receptors. Its approved uses depend on the product and jurisdiction, rather than following automatically from its dual-receptor mechanism.

SURMOUNT-1 studied adults with obesity or overweight without diabetes. SURMOUNT-5 directly compared specified maximum-tolerated tirzepatide and semaglutide regimens, with an open-label design. Neither trial compares every later formulation or settles suitability for an individual.

The US sleep-apnea approval has a defined adult population. It is not advice to stop positive-airway-pressure treatment independently. The appropriate care team should review changes.

The applicable label remains the source for contraindications and warnings. This profile does not recommend combining medicines, selecting a dose, or substituting products.

Regulatory status checked on 3 October 2026

United States: Zepbound is FDA-approved for specified adult weight-management uses and moderate-to-severe obstructive sleep apnea in adults with obesity. Product-label restrictions apply.

European Union: EMA Mounjaro record documents EU authorisation for specified diabetes and adult weight-management uses. The US and EU product indications are independently described.

Official records and primary evidence

Route and frequency describe approved product records or clinical-trial protocols as identified above. They are not instructions to use, obtain, combine, or dose a medicine. This record is informational and has not been independently medically reviewed.

Official references

  1. US Zepbound prescribing information ↗
  2. FDA Zepbound sleep-apnea indication ↗
  3. EU Mounjaro product record ↗
  4. SURMOUNT-1 obesity trial ↗
  5. SURMOUNT-5 direct comparison ↗

Clinical trial evidence

Registry status and published results are shown separately. Treatment averages across different studies are not a ranking or a prediction for an individual.

SURMOUNT-1

NCT04184622 · Tirzepatide profile

Sponsor
Eli Lilly and Company
Phase
Phase 3
Registry status
completed
Registry enrollment
2539 (actual)
Published analysis population
2539
Analysis time point
72 weeks
Population
Adults with obesity, or overweight with weight-related complications, without diabetes. Exact eligibility differs by trial; consult the linked protocol.
Registry checked
2026-10-03

Registry actual enrollment and published randomized population both equal 2539.

Published mean body-weight change at 72 weeks · treatment-regimen (intention-to-treat)
Historical trial armMean change from baseline
tirzepatide 5 mg trial arm-15.0%
tirzepatide 10 mg trial arm-19.5%
tirzepatide 15 mg trial arm-20.9%
placebo-3.1%

Negative values indicate a decrease from baseline. Arm dose labels describe the research protocol, not a dosing recommendation.

Original study abstract · Full registry record

The original abstract and registry were checked; full texts and supplements were not independently reviewed. Confidence intervals absent from this record must not be inferred. These selected results do not describe every safety finding or subgroup.

Evidence, explainers and reporting

The medicine profile is a reference point. These articles address narrower questions and developments.

← Back to the drug tracker
Cookie policy